Scope Fluidics SA - Asset Resilience Ratio
Scope Fluidics SA (SCP) has an Asset Resilience Ratio of 16.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Scope Fluidics SA's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Scope Fluidics SA to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Scope Fluidics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Scope Fluidics SA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł23.40 Million | 16.51% |
| Total Liquid Assets | zł23.40 Million | 16.51% |
Asset Resilience Insights
- Good Liquidity Position: Scope Fluidics SA maintains a healthy 16.51% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Scope Fluidics SA Industry Peers by Asset Resilience Ratio
Compare Scope Fluidics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Predilife
PA:ALPRE |
Diagnostics & Research | 16.23% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Scope Fluidics SA (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Scope Fluidics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.84% | zł22.19 Million ≈ $6.11 Million |
zł172.87 Million ≈ $47.58 Million |
-7.76pp |
| 2023-12-31 | 20.60% | zł20.90 Million ≈ $5.75 Million |
zł101.49 Million ≈ $27.93 Million |
-- |
About Scope Fluidics SA
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.